Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Sun Pharmaceutical Industries Ltd
Gross Profit
Sun Pharmaceutical Industries Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Gross Profit
₹411.1B
|
CAGR 3-Years
14%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Gross Profit
₹220.1B
|
CAGR 3-Years
17%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Gross Profit
₹181.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Gross Profit
₹152.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Gross Profit
₹85.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Gross Profit
₹69.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sun Pharmaceutical Industries Ltd
Glance View
Sun Pharmaceutical Industries Ltd. began its journey in 1983 with a vision to provide quality healthcare to billions worldwide. Originating from India, Sun Pharma has steadily emerged as a global leader in the pharmaceutical industry. The company’s strength stems from its ability to efficiently manufacture, develop, and market a wide range of generic pharmaceuticals and therapeutic formulations. With a significant footprint in over 100 countries, it is driven by a robust pipeline of drugs encompassing key therapeutic areas such as psychiatry, cardiology, neurology, and gastroenterology. A hallmark of Sun Pharma’s strategy has been its strong focus on research and development, specifically in creating affordable medicines that tackle complex medical conditions. The company’s business model revolves around a dual strategy: the development of complex generics and innovative specialty products. This approach allows Sun Pharma to capitalize on both the high-volume, cost-efficient production of off-patent drugs and the value-driven, specialized therapy segments. By leveraging its R&D capabilities, the company explores new drug delivery systems and complex formulations, which not only ensure a steady flow of new product introductions but also enhance its competitive edge in the market. This blend of innovation and scale positions Sun Pharmaceutical Industries Ltd. as a dynamic force in the global pharmaceutical landscape, continually navigating the intricate balance of providing both profitable growth and accessible healthcare solutions.
See Also
What is Sun Pharmaceutical Industries Ltd's Gross Profit?
Gross Profit
411.1B
INR
Based on the financial report for Dec 31, 2024, Sun Pharmaceutical Industries Ltd's Gross Profit amounts to 411.1B INR.
What is Sun Pharmaceutical Industries Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
8%
Over the last year, the Gross Profit growth was 11%. The average annual Gross Profit growth rates for Sun Pharmaceutical Industries Ltd have been 14% over the past three years , 12% over the past five years , and 8% over the past ten years .
You don't have any saved screeners yet